Forearm Immobilization in T2D

Wageningen University26 enrolled

Overview

The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.

Participants with and without T2D will undergo 2 days of forearm immobilization as a model of local physical inactivity. Before, throughout, and after immobilization arteriovenous forearm balance measurements will be combined with a stable isotope tracer infusion to measure muscle glucose uptake and amino acid balance, uptake, and efflux.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Type 2 Diabetes

Interventions

Forearm immobilizationBEHAVIORAL

Two days of forearm immobilization

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria * Males and females with or without diagnosed type 2 diabetes * Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D * Aged 18-80 years at the time of signing informed consent * 18.5 ≥ BMI ≤ 35 kg·m2 Exclusion criteria * Type 1 or a genetic form of diabetes * Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic) * Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors) * Consumption of a low-carbohydrate diet * Smoking or chewing tobacco * Known anaemia * Regular use of dietary protein and/or amino acid supplements (\>3 times per week) * Currently involved in a structured progressive resistance training program (\>3 times per week) * A personal or family history of thrombosis (clots) * Any previous motor disorders or inborn errors in muscle and/or lipid metabolism * History of kidney disease * History of liver disease * Pregnant or breastfeeding * History of any drug or alcohol abuse in the past two years * Claustrophobia * Unable to give consent

Locations (1)

Wageningen University and Research

Wageningen, Gelderland, Netherlands

RECRUITING

Outcomes

Primary Outcomes

Change in forearm muscle glucose uptake

The change in postprandial muscle insulin sensitivity, measured as forearm glucose uptake, from pre-immobilization to post-immobilization

Time frame: From 0 to 48 hours

Secondary Outcomes

Temporal change in forearm glucose uptake

The change in postprandial muscle insulin sensitivity, measured as the temporal response of forearm glucose uptake (FGU), in response to repeated meals during 48 hours of forearm immobilization

Time frame: Prior to and for 3.5 hours following every meal consumption during the 48 hours forearm immobilization period

Change in forearm muscle amino acid kinetics

Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the rate of appearance (Ra) of phenylalanine across the forearm.

Time frame: Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours)

Change in forearm muscle amino acid kinetics

Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the rate of disappearance (Rd) of phenylalanine across the forearm.

Time frame: Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours)

Change in forearm muscle amino acid kinetics

Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the net balance (NB) of phenylalanine across the forearm.

Time frame: Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours)

Central Contacts

Marlou Dirks, PhD

CONTACT

+31 317 480 100 marlou.dirks@wur.nl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.